Hemostasis

Baxter Showcases Surgical Innovations at AORN Global Surgical Conference and Expo 2023

Retrieved on: 
Monday, April 3, 2023
Surgery, Medical Devices, Hospitals, Health, Medical Supplies, DNA, Association of periOperative Registered Nurses, OR, Thrombin, PST, Baxter International, Information International, Inc., Thermoregulation, Perioperative, Hemostasis, AORN, Patient, Bleeding, Conference, NYSE, Nursing, Medical device

Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.
  • The system is also air-free, which may reduce risks associated with forced air systems1—such as contamination of the surgical site—and operates quietly.
  • The Baxter Patient Warming system is compatible with its TS7000, TS7000dV and PST 500 surgical tables.
  • Baxter also revealed a first look at its Helux Pro Connected Surgical Light, a wired lighting and camera solution for the operating room.

Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler

Retrieved on: 
Wednesday, March 29, 2023
Titan, Pressure, Partnership, Surgeon, Bleeding, Business Leaders for Michigan, TFX, Staple (fastener), Hemostasis, Device, MD, Bariatrics, Bariatric surgery, FDA, News, NYSE, Dentistry, Teleflex

With these two innovative technologies paired together, bariatric surgeons will be able to utilize the advanced technology of the Titan SGS® Device with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement material.

Key Points: 
  • With these two innovative technologies paired together, bariatric surgeons will be able to utilize the advanced technology of the Titan SGS® Device with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement material.
  • The powered stapling Titan SGS® Device offers a range of benefits:
    GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement is a synthetic buttressing material engineered to reduce leaks and bleeding and strengthen the staple line by redistributing the pressure exerted by an individual staple over a wider area5.
  • In addition to the Titan SGS® Device, GORE® SEAMGUARD® Reinforcement material can be used with a variety of surgical staplers.
  • I am excited to hear it will be an option for surgeons using the Titan SGS® Platform for sleeve gastrectomy.”

Latin America Vitro Diagnostic (IVD) Tests Market Research Report 2023: Focus on Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela - ResearchAndMarkets.com

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Science, Health, Research, Syphilis, Blood, Interleukin, Autoimmunity, Hormone, Molecular biology, Market, Other Nationalities rugby league team, Histology, Toxicology, Torch, NAT, POC, Leukemia, CT, Pregnancy, Gram, Microbiology, Medium (website), DSM-IV codes, Infection, Flow cytometry, FDP, NG, HPV, BNP, Blood culture, EBV, Allergy, COVID-19, MRSA, Fibrinogen, Hepatitis, AIDS, Hemostasis, Anemia, CMV, IVD, APTT, Glycated hemoglobin, Lymphoma, TSH, Fecal occult blood, HIV, Control, PCT, Thrombosis, MTB, Fertility, Coagulation, Cardiology, LATAM, Drug, Vaccine, Medical imaging, Ureaplasma, Sepsis, Mycoplasma, Myoglobin

The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for In Vitro Diagnostic (IVD) Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and Other Nations)" report has been added to ResearchAndMarkets.com's offering.
  • This market report focuses on the market for reagents and instruments in the most important countries of the region.
  • Brazil and Mexico represent the two largest countries in terms of population, accounting for more than half of LATAM total population.
  • For this reason, these two countries have been the focus of many IVD suppliers in recent years.

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

Retrieved on: 
Wednesday, March 8, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Woman, CSO, Clinical trial, Regenerative medicine, American Heart Association, Bleeding, Dialysis, Bangladesh Technical Education Board, American Board of Commissioners for Foreign Missions, Moyamoya disease, Leiden University Medical Center, Pathology, VASA, Department of Defense Serum Repository, Coagulation, Hemostasis, Special, Duke University Hospital, Knowledge, Tissue engineering, Coagulopathy, NIH, Pharmaceutical industry, Medical device, KHI

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).

Key Points: 
  • VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).
  • Dr. Lawson will take over the role from Prof. Dr. Pieter Reitsma, CSO and founder of VarmX, who will continue to serve as a special advisor to the Company.
  • Dr. Lawson and Prof. Dr. Reitsma will work closely to ensure a smooth transition and the continued scientific development of the company’s innovative technologies.
  • Dr. Jan Öhrström, CEO of VarmX, said: “We are delighted to welcome Jeff to the team at VarmX.

Tricol Biomedical Expands IP Protection with First New Patent for Gastrointestinal Hemostasis

Retrieved on: 
Tuesday, February 21, 2023
Patent, United States patent law, OR, Bleeding, Maintenance, Hemostasis, Extrapyramidal system, Research, Family, Chitosan, Thibault Tricole, Death, GI

The patent – the first of its kind for Tricol Biomedical – will protect intellectual property surrounding this modified chitosan dressing designed to provide easy delivery with prolonged safe and effective use within the GI tract.

Key Points: 
  • The patent – the first of its kind for Tricol Biomedical – will protect intellectual property surrounding this modified chitosan dressing designed to provide easy delivery with prolonged safe and effective use within the GI tract.
  • Tricol’s proprietary chitosan-based hemorrhage control platform, branded as Chito+™, has been demonstrated to control serious bleeding quickly and safely, with excellent maintenance of bleeding control.
  • “Prolonged bleeding in the upper gastrointestinal tract is a significant problem in the emergency room and in acute care settings,” commented Christopher Rowland, President and CEO of Tricol Biomedical.
  • The company holds over 60 patents with its technology documented in over 30 clinical publications.

Stago to Host "Heparin-Induced Thrombocytopenia (HIT): Practical Aspects of Clinical and Laboratory Diagnosis" Virtual Event, February 22nd, 2023

Retrieved on: 
Thursday, February 9, 2023
Clinical pathology, Science, Thrombosis, HIT, Hemostasis, Labroots, Incidence, Heparin, Dentistry

PARSIPPANY, N.J., Feb. 9, 2023 /PRNewswire-PRWeb/ -- Stago to host their "Heparin-Induced Thrombocytopenia (HIT): Practical Aspects of Clinical and Laboratory Diagnosis" webinar on February 22nd, 2023, available any time after 1 pm Eastern Daylight time on the Labroots platform.

Key Points: 
  • Don't miss an opportunity to join Stago, an industry leader in the science of hemostasis and thrombosis, for a new educational webinar
    PARSIPPANY, N.J., Feb. 9, 2023 /PRNewswire-PRWeb/ -- Stago to host their "Heparin-Induced Thrombocytopenia (HIT): Practical Aspects of Clinical and Laboratory Diagnosis" webinar on February 22nd, 2023, available any time after 1 pm Eastern Daylight time on the Labroots platform.
  • At Stago's Virtual Event , expect to learn about Heparin-Induced Thrombocytopenia (HIT), a life-threatening complication following heparin exposure.
  • The event will dive into the pathogenesis, incidence, clinical and laboratory diagnosis, as well as management of HIT.
  • Join this Virtual Event to:
    To register for the event, and view the agenda, click here .

Global In-Vitro Diagnostics (IVD) Market Report 2022: Sector to Reach $144.7 Billion by 2027 at a 4.6% CAGR

Retrieved on: 
Sunday, January 22, 2023
USD, Cardiology, Diagnosis, Diabetes, Microbiology, Data management, IVD, Immunoassay, Growth, Government, Region, Hemostasis, Infection, Prevalence, POC, Hospital, HIV/AIDS, Patient, Coagulation, Hospital Clinic Manuel Quintela, Nephrology, Medical device, Urinalysis, Software, Hematology

The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.

Key Points: 
  • The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.
  • On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The IVD market in the Asia-Pacific region is projected to register the highest CAGR during the forecast period.

Global In-Vitro Diagnostics (IVD) Market Report 2022: Introduction of Disease-Specific Biomarkers and Tests Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Medical Devices, Hospital, Degenerative disease, Immunoassay, Infection, Hemostasis, HIV/AIDS, Clifton Springs Hospital & Clinic, POC, Microbiology, Nephrology, Government, IVD, Coagulation, Cardiology, Urine test strip, Diagnosis, Growth, Diabetes, Region, Prevalence, Patient, Data management, USD, Medical device, Clinical urine tests, Software, Hematology

The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.

Key Points: 
  • The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.
  • On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software.
  • The reagents & kits segment accounted for the largest share of the IVD market in 2021.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.

First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants

Retrieved on: 
Tuesday, January 3, 2023
Thrombolysis, Clinical trial, Anticoagulant, Harvard Medical School, Stroke, Factor XI, Therapy, Hope, Health, Risk, Hemostasis, TIMI, Anthos, Patient, American Foundation for Children with AIDS, Myocardial infarction, AF, Thrombosis, Bleeding, Safety, Kidney, Rivaroxaban, Atrial fibrillation, MPH, Hospital, Pharmaceutical industry, MD, Brigham, Medicine

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced that it has enrolled the first patient in LILAC-TIMI 76, a Phase 3 study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation (AF) deemed unsuitable for current anticoagulants by their physician. The study is targeting to enroll approximately 1900 patients from more than 300 sites across North America, Europe, Latin America, and Asia.

Key Points: 
  • The study is targeting to enroll approximately 1900 patients from more than 300 sites across North America, Europe, Latin America, and Asia.
  • Data from multiple registries show that approximately 40% of AF patients are not being optimally treated todayi,” said Dan Bloomfield, M.D., Chief Medical Officer at Anthos.
  • It is an event driven phase 2b study evaluating the safety and tolerability of abelacimab compared head-to-head with rivaroxaban in 1287 patients with atrial fibrillation at moderate-to-high risk of stroke.
  • Anthos is also enrolling patients in GARDENIA, a large international patient registry designed to evaluate treatment patterns and outcomes in segments of the atrial fibrillation population that have conditions associated with an increased risk of bleeding.

Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Retrieved on: 
Wednesday, December 21, 2022
Blood, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD, Hemostasis, Hematochezia, EVS, Research, Patient, Mortality, GI, Physician, Bleeding, FDA, Suction, Endoscopy, Diagnosis, Medical device, Pharmaceutical industry, Gastroenteritis

Recently, the Company successfully completed multiple pre-clinical tests in both porcine and cadaver models to evaluate Pure-Vu EVS platform for use in upper GI bleeding with multiple U.S. physicians.

Key Points: 
  • Recently, the Company successfully completed multiple pre-clinical tests in both porcine and cadaver models to evaluate Pure-Vu EVS platform for use in upper GI bleeding with multiple U.S. physicians.
  • The Company plans on conducting additional pre-clinical and clinical tests for Pure-Vu EVS Gastro device in the first half of 2023.
  • “We are excited to announce the significant progress we’ve made in developing our Pure-Vu EVS Gastro for use with both diagnostic and therapeutic gastroscopes in upper GI bleeding procedures.
  • Over the coming quarters, we will evaluate enhancing the planned commercial program for Pure-Vu EVS in upper GI through potential strategic distribution and licensing partnerships.